SCHEMBL7344349

SCHEMBL7344349

N=C(N)c1ccc2cc(C(=O)Nc3cccc(OCc4ccccc4)c3)ccc2c1

nearest known ligand 0.74

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PLAU P00749 11/20 0.74
PLG P00747 6/20 0.67
PLAT P00750 5/20 0.67
KLKB1 P03952 5/20 0.67
PRSS1 P07477 5/20 0.67
F2 P00734 4/20 0.67
KLK1 P06870 1/20 0.67
NR1H4 Q96RI1 3/20 0.65
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
SIRT2 Q8IXJ6 1/20 0.58
SIRT1 Q96EB6 1/20 0.58
SIRT3 Q9NTG7 1/20 0.58
NPC1 O15118 2/20 0.57
RAB9A P51151 2/20 0.57
RXFP1 Q9HBX9 1/20 0.57
F10 P00742 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7449026 0.90 NR1H4 (0.72) PLAUNR1H4MEN1KMT2ASIRT2
SCHEMBL7344439 0.85 PLAU (1.00) PLAUPLGPLATKLKB1PRSS1
SCHEMBL7337835 0.85 PLAU (1.00) PLAUPLGPLATKLKB1PRSS1
SCHEMBL14132190 0.84 F2 (0.66) PLAUF2NR1H4SIRT2SIRT1
SCHEMBL11550139 0.83 NR1H4 (0.81) NR1H4MEN1KMT2ANPC1RAB9A
SCHEMBL7342729 0.83 PLAU (0.83) PLAUPLGPLATKLKB1PRSS1
SCHEMBL7344354 0.82 NR1H4 (0.59) PLAUNR1H4MEN1KMT2ASIRT2
SCHEMBL4324160 0.82 PLAU (1.00) PLAUPLGPLATKLKB1PRSS1
SCHEMBL7365142 0.81 PLAU (0.80) PLAUPLGPLATKLKB1PRSS1
Trifluoroacetic Acid SCHEMBL7853915 0.81 PLAU (0.86) PLAUPLGPLATKLKB1PRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 PLAU 2/4885PLG 10/4885PLAT 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.